Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 9, 2025Frontiers in PharmacologyOpen Access

Pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in the C57BL/6Crl mouse

View Full Paper
Ask AI
Bookmark
Share

Authors

AZAyat ZagzoogKHKenzie HalterNHNgan Tran Ha

Discussion

Loading...

Member takes

Overview

Experiments assess pharmacokinetics and pharmacodynamics of CBG in C57BL/6Crl mice, indicating its non-intoxicating nature.

Key Points

  • This research aims to evaluate the pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in C57BL/6Crl mice.
  • Assessed pharmacokinetics and pharmacodynamics of CBG in C57BL/6Crl mice.
  • Conducted blood sampling at various time points after oral, intraperitoneal, and intravenous administration.
  • Measured blood concentrations of CBG using HPLC-MS/MS to determine pharmacokinetics.
  • Tested locomotor, cataleptic, and hypothermic effects to evaluate pharmacodynamics.
  • CBG was found to be non-intoxicating regardless of route of administration.
  • Pharmacokinetics of CBG were detailed through blood sampling.
  • Data supports previous findings that CBG does not produce intoxicating effects like THC.

Cite This Study

Zagzoog et al. (2025) studied this question.

synapsesocial.com/papers/69401d5b2d562116f28f8ba3https://doi.org/10.3389/fphar.2025.1672098
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<b>The Intoxication Equivalency of 11-Hydroxy-Δ<sup>9</sup>-tetrahydrocannabinol (11-OH-THC) Relative to Δ<sup>9</sup>-tetrahydrocannabinol (THC)</b>2024 · 4 citations
  2. 2Effects of cannabinoids and cannabinoid‐enriched <i>Cannabis</i> extracts on TRP channels and endocannabinoid metabolic enzymes2010 · 952 citations
  3. 3The Pharmacological Case for Cannabigerol2020 · 200 citations
  4. 4Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms2021 · 54 citations
  5. 5Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C192013 · 197 citations